CA
NZ
UK
AU
IND
US
Jasper Therapeutics entered 2026 as a struggling clinical-stage biotech and has since reinvented itself through dealmaking. The stock still trades below $1, near $0.70 with a marketCapitalizationaround $23 million, but the company behind ticker JSPR looks materially different than it did in the spring, …
Jupiter Neurosciences (NASDAQ:JUNS) has packed a lot into its short public life, and the stock's recent stability comes as the company pushes a resveratrol-based neurology pipeline alongside a newly launched consumer longevity brand. Trading around three dollars, the Jupiter, Florida micro-cap is trying to …
KALA BIO (NASDAQ:KALA) has spent 2026 remaking itself, and the small daily uptick reflected in recent trading data arrives against a backdrop of dramatic corporate restructuring rather than a single headline event. The Massachusetts company, once known chiefly for its ophthalmology franchise, executed a …
Kairos Pharma, Ltd. (NYSE American:KAPA) sits at the speculative edge of the oncology sector, a clinical-stage biopharmaceutical company with aMarket Valueof only a few million dollars and a pipeline aimed squarely at one of cancer's toughest problems: drug resistance. Shares of the Los Angeles-based …
Few tickers illustrate the extreme end of small-cap biotech quite like Innovation Pharmaceuticals. Trading at a fraction of a penny on the over-the-counter market, Innovation Pharmaceuticals Inc (OTC: IPIX) is a clinical-stage company whose long-running drug candidate has generated scientific interest but little recent …
IRIDEX Corporation (NASDAQ:IRIX) has spent much of 2026 stuck in a narrow, low-priced trading band, and the latest session did little to disturb that pattern. Trading around $0.68 near the bottom of its 52-week range, the ophthalmic device maker looks like a company caught …
● Unlike most names generating attention through dramatic swings, InMode has been notable for how little its shares have moved, hovering near $14.79 while a boardroom-level tug-of-war plays out beneath the surface.
● Inovio Pharmaceuticals is approaching one of the most consequential moments in its long history, with a key regulatory decision on its lead DNA medicine drawing near.
● Insmed has transformed itself from a one-product rare-disease company into one of the most closely followed names in mid-to-large-cap biopharma.
● The advance coincided with Inspire's scheduled presentation at the Wells Fargo 21st Annual Healthcare Conference on 9 September, where management reiterated an outlook for sequentialRevenuegrowth in the second half and emphasised newer closed-loop technology and clearer reimbursement coding.
Please wait processing your request...